$ALMS

Goldstein David M sold $68K of ALMS

Goldstein David M (Chief Scientific Officer) sold 2,596 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Goldstein David M
Published Aug 5, 2026, 10:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the Chief Scientific Officer.

02

Market read

Traders may note insider selling, but there is no accompanying guidance, contract, or regulatory development in the text.

03

What to watch

The filing does not state a 10b5-1 plan, but it also provides no reason for the sale, so interpreting it as information is speculative.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS disclosed a Form 4 showing Chief Scientific Officer David M Goldstein sold 2,596 shares at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no company-specific operational or financial change.

Market effects

No sector-level signal; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management and not a bearish signal, especially since insider sales frequently occur without any subsequent negative company news.

Key entities

  • ALUMIS INC.

    Company subject of the Form 4 insider transaction disclosure.

  • David M Goldstein

    Chief Scientific Officer who sold 2,596 shares.

Related articles

$ALMSMedAI 9/10

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Alumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.